Name: Latest research reports of Lupin Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 1
Author: ICICI Securities Limited

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Mid-range Performer

2027.9500 9.15 (0.45%)

NSE Mar 28, 2025 15:31 PM

35.80% Gain from 52W Low

Volume: 828.4K

Lupin Ltd.

13 Feb 2023

2027.95

0.45%

US delivers; margin recovery on track

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s Q3FY23 performance was a beat on revenue front led by better than expected US sales. Revenue grew 3.9% YoY and 4.3% QoQ to Rs43.2bn (I-Sec: Rs41.4bn). US revenue was up 11.3% QoQ at US$177mn (I-Sec:US$172mn) led by new product launches (~US$20mn) and benefit from flu season.

Number of FII/FPI investors increased from 925 to 964 in Dec 2024 qtr.